Skip to main content
Bohn Stafleu van Loghum
ZOEKEN
MENU 1 2 3 4
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Quality of Life Research 8/2016

01-08-2016

Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice

Auteurs: N. H. Shear, M. Hartmann, M. E. Toledo-Bahena, M. Gilbert, A. Katsambas, R. Yao, Z. Popmihajlov

Gepubliceerd in: Quality of Life Research | Uitgave 8/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

We evaluated the effect of plaque-type psoriasis on health-related quality of life (HRQoL) of patients who received infliximab (IFX) in real-world clinical settings.

Methods

REALITY was a prospective, observational, open-label study of the efficacy and safety of up to 98 weeks of IFX (5 mg/kg infused at weeks 0, 2, 6, and every 8 weeks thereafter) in patients with moderate-to-severe plaque-type psoriasis. Patients with ≥25 % Psoriasis Area Severity Index (PASI) improvement (PASI 25) at week 50 were eligible for the Extended Treatment Phase (treatment to week 98). Inclusion criteria were diagnosis of plaque-type psoriasis, age ≥18 years, decision to start IFX, and patient consent. Key secondary efficacy outcomes included the Dermatologic Life Quality Index (DLQI; mean DLQI scores, attainment of DLQI 0/1), which was analyzed over 98 weeks. Post hoc analyses examined improvement in DLQI and the relationship between PASI and DLQI.

Results

In the Treatment Phase, patients (n = 516, 66.0 % men, mean age 46.4 years) had a mean baseline PASI of 18.1. Mean DLQI improved from 12.7 at baseline to 4.7 [mean change (95 % CI); −8.0 (−8.9, −7.1)] at week 50; 64.0 % (229/358) of patients improved by ≥5 DLQI points. At week 50 (n = 362), 37.6 % (95 % CI; 32.7, 42.7) achieved a DLQI of 0. In the Extended Treatment Phase, patients (n = 167, 68.3 % men, mean age 46.6 years) had a mean baseline PASI of 20.4. Mean DLQI improved from 12.3 at baseline to 2.8 at week 98 [mean change (95 % CI); −9.4 (−10.8, −8.0)]; 68.6 % (96/140) of patients improved by ≥5 DLQI points. At week 98 (n = 141), 47.5 % (95 % CI; 39.4, 55.7) achieved a DLQI of 0.

Conclusions

Patients with plaque-type psoriasis who received treatment with IFX for 50 weeks or up to 98 weeks reported substantial HRQoL improvement.
vorige artikel Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome
volgende artikel Fluctuating patterns in quality of life outcomes among patients with moderate and severe stages of chronic obstructive pulmonary disease
Literatuur
1.
Ahn, C. S., Gustafson, C. J., Sandoval, L. F., Davis, S. A., & Feldman, S. R. (2013). Cost effectiveness of biologic therapies for plaque psoriasis. American Journal of Clinical Dermatology, 14, 315–326. CrossRefPubMed
2.
Baker, E. L., Coleman, C. I., Reinhart, K. M., et al. (2012). Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses. Dermatology and Therapy, 2, 9. CrossRefPubMedPubMedCentral
3.
Basra, M. K. A., Fenech, R., Gatt, R. M., et al. (2008). The Dermatology Life Quality Index 1994–2007: A comprehensive review of validation data and clinical results. British Journal of Dermatology, 159, 997–1035.
4.
Feldman, S. R., Gottlieb, A. B., Bala, M., et al. (2008). Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. British Journal of Dermatology, 159, 704–710. CrossRefPubMed
5.
Finlay, A. Y., & Khan, G. K. (1994). Dermatology life quality index (DLQI)—A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19, 210–216. CrossRefPubMed
6.
Finlay, A. Y., & Ryan, T. J. (1996). Disability and handicap in dermatology. International Journal of Dermatology, 35, 305–311. CrossRefPubMed
7.
Fredriksson, T., & Pettersson, U. (1978). Severe psoriasis—oral therapy with a new retinoid. Dermatology, 157, 238–244. CrossRef
8.
Gottlieb, A. B., Evans, R., Li, S., et al. (2004). Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 51, 534–542. CrossRefPubMed
9.
Hongbo, Y., Thomas, C. L., Harrison, M. A., Salek, M. S., & Finlay, A. Y. (2005). Translating the science of quality of life into practice: What do dermatology life quality index scores mean? Journal of Investigative Dermatology, 125, 659–664. CrossRefPubMed
10.
Khilji, F. A., Gonzalez, M., Finlay, A. Y. (2002). Clinical meaning of change in Dermatology Life Quality Index scores. British Journal of Dermatology, 147(suppl 2), 50.
11.
Krueger, G., Koo, J., Lebwohl, M., Menter, A., Stern, R. S., & Rolstad, T. (2001). The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Archives of Dermatology, 137, 280–284. PubMed
12.
McKenna, K. E., & Stern, R. S. (1997). The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. Journal of the American Academy of Dermatology, 36(3 Pt 1), 388–394. CrossRefPubMed
13.
Menter, A., & Griffiths, C. E. M. (2007). Current and future management of psoriasis. Lancet, 370, 272–284. CrossRefPubMed
14.
Menter, A., Feldman, S. R., Weinstein, G. D., et al. (2007). A randomized comparison of continuous versus intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology, 56(31), e1–e15. PubMed
15.
Mrowietz, U., Kragballe, K., Reich, K., et al. (2011). Definition of treatment goals for moderate to severe psoriasis: A European consensus. Archives of Dermatological Research, 303, 1–10. CrossRefPubMed
16.
Nelson, A. A., Pearce, D. J., Fleischer, A. B, Jr, Balkrishnan, R., & Feldman, S. R. (2008). Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. Journal of the American Academy of Dermatology, 58, 125–135. CrossRefPubMed
17.
Raho, G., Koleva, D. M., Garattini, L., & Naldi, L. (2012). The burden of moderate to severe psoriasis: An overview. Pharmacoeconomics, 30, 1005–1013. CrossRefPubMed
18.
Shao, J., Jordan, D. C., & Pritchett, Y. L. (2009). Baseline observation carry forward: Reasoning, properties, and practical issues. Journal of Biopharmaceutical Statistics, 19(4), 672–684. CrossRefPubMed
19.
Shear, N. H., Hartmann, M., Toledo-Bahena, M., REALITY investigators, et al. (2014). Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice. British Journal of Dermatology, 171, 631–641. CrossRefPubMed
20.
Zweegers, J., van den Reek, J. M., van de Kerkhof, P. C., et al. (2014). Comparing treatment goals for psoriasis to treatment decisions in daily practice: Results from a prospective cohort of psoriasis patients treated with biologics: BioCAPTURE. British Journal of Dermatology, 171(5), 1091–1098. doi: 10.​1111/​bjd.​13137. CrossRefPubMed
Metagegevens
Titel
Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice
Auteurs
N. H. Shear
M. Hartmann
M. E. Toledo-Bahena
M. Gilbert
A. Katsambas
R. Yao
Z. Popmihajlov
Publicatiedatum
01-08-2016
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 8/2016
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-015-1224-z

Andere artikelen Uitgave 8/2016

Quality of Life Research 8/2016 Naar de uitgave

OriginalPaper

Impact of nine chronic conditions for US adults aged 65 years and older: an application of a hybrid estimator of quality-adjusted life years throughout remainder of lifetime

OriginalPaper

The validity and responsiveness of the ICECAP-A capability-well-being measure in women with irritative lower urinary tract symptoms

OriginalPaper

How different are composite and traditional TTO valuations of severe EQ-5D-5L states?

Brief Communication

The effect of response option order on self-rated health: a replication study

Review

Patient-reported outcome measures for cancer caregivers: a systematic review

OriginalPaper

Health-related quality of life among veterans in addictions treatment: identifying behavioral targets for future intervention